Literature DB >> 20523781

Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.

Eun Ah Cho1, Myung Ah Lee, Hoon Kang, Seung Dong Lee, Hyung Ok Kim, Young Min Park.   

Abstract

Although malignant melanoma usually occurs after the diagnosis of vitiligo-like depigmentation, the latter is rarely followed by the former. We herein report on such a case in which recognition of the vitiligo-like depigmentation preceded diagnosing the metastatic melanoma by several months. A 56-year-old woman had first developed vitiligo-like depigmentation on the forehead, eyelids, neck and back 18 months previously and thereafter she detected a hard mass in the left axilla 2 months previously. Based on the histologic findings, the axillary mass was diagnosed as metastatic melanoma. To evaluate the primary tumor focus, thorough examinations that included PET-CT, bone scan and sigmoidoscopy were performed, but we couldn't find any the original primary tumor. Our case suggests that the vitiligo-like depigmentation could be a sign that heralds metastatic melanoma.

Entities:  

Keywords:  Metastatic melanoma; Vitiligo-like depigmentation

Year:  2009        PMID: 20523781      PMCID: PMC2861199          DOI: 10.5021/ad.2009.21.2.178

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  16 in total

1.  Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.

Authors:  F A Le Gal; M F Avril; J Bosq; P Lefebvre; J C Deschemin; M Andrieu; M X Dore; J G Guillet
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

Review 2.  Regressing cutaneous malignant melanoma and vitiligo-like depigmentation.

Authors:  Nicola Arpaia; Nicoletta Cassano; Gino A Vena
Journal:  Int J Dermatol       Date:  2006-08       Impact factor: 2.736

3.  Vitiligo-like depigmentation as a presenting sign of metastatic melanoma.

Authors:  F Kiecker; M Hofmann; W Sterry; U Trefzer
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-10       Impact factor: 6.166

Review 4.  Melanoma and vitiligo: immunology's Grecian urn.

Authors:  D Berd; M J Mastrangelo; E Lattime; T Sato; H C Maguire
Journal:  Cancer Immunol Immunother       Date:  1996-06       Impact factor: 6.968

5.  Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study.

Authors:  H K Koh; A J Sober; H Nakagawa; D M Albert; M C Mihm; T B Fitzpatrick
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

6.  Prolonged survival in metastatic malignant melanoma associated with vitiligo.

Authors:  P Duhra; A Ilchyshyn
Journal:  Clin Exp Dermatol       Date:  1991-07       Impact factor: 3.470

7.  [Hypomelanosis of the skin and malignant melanoma (author's transl)].

Authors:  J P Ortonne; Y Gauthier; G Guillet; O Gauthier
Journal:  Ann Dermatol Venereol       Date:  1978-12       Impact factor: 0.777

Review 8.  Immunohistochemical characteristics of melanoma.

Authors:  Steven J Ohsie; G Peter Sarantopoulos; Alistair J Cochran; Scott W Binder
Journal:  J Cutan Pathol       Date:  2008-05       Impact factor: 1.587

9.  Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.

Authors:  J Cui; J C Bystryn
Journal:  Arch Dermatol       Date:  1995-03

10.  Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

Authors:  C Yee; J A Thompson; P Roche; D R Byrd; P P Lee; M Piepkorn; K Kenyon; M M Davis; S R Riddell; P D Greenberg
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  3 in total

1.  Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?

Authors:  Julio Cesar Salas-Alanis; Roger Gonzalez; Giulio Fortuna
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

2.  Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.

Authors:  Jomjit Chantharasamee; Jitsupa Treetipsatit
Journal:  Case Rep Oncol Med       Date:  2018-05-31

Review 3.  STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.

Authors:  Stella Logotheti; Brigitte M Pützer
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.